Suggested Remit: To appraise the clinical and cost effectiveness of ramucirumab with erlotinib within its marketing authorisation for treating epidermal growth factor receptor (EGFR)-positive metastatic non-small-cell lung cancer that has not previously been treated.
Status In progress
Process STA 2018
ID number 1665

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
11 November 2019 - 09 December 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
24 April 2018 In progress, DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance